《中国药典》成方制剂中何首乌药对配伍规律分析
|
摘要
目的总结并分析何首乌在《中国药典》2015年版成方制剂中的配伍规律。方法以《中国药典》2015年版收载的含有何首乌的成方制剂作为数据来源,统计何首乌配伍药物的名称、功效分类、组分信息,建立数据库,关联何首乌配伍药对并分析主要配伍组分。结果共计纳入55个复方,有253味中药及3种单体药物与何首乌配伍应用。配伍药物以植物药为主,按功效分类主要包括补虚药56味(22.13%)、活血化瘀药22味(8.70%)、清热药19味(7.51%)、祛风湿药18味(7.11%)、理气药17味(6.72%)、解表药13味(5.14%)、平肝熄风药13味(5.14%)、安神药12味(4.74%)。关联分析得到36个何首乌药对,并将配伍药物依据所含组分不同分为4类,配伍组分以多糖、皂苷、黄酮及苷类化合物为主。结论何首乌在成方制剂中主要与补虚药、活血化瘀药进行配伍使用,配伍组分类型主要为多糖、皂苷、黄酮、苷类化合物,其次为萜类、甾体、生物碱、有机酸类物质,以期为反映何首乌配伍规律及机制研究提供参考。
Objective To summarize the compatibility rules of Polygonum multiflorum in different formulations in Chinese pharmacopoeia(2015 Edition). Methods Preparations containing Polygonum multiflorum were used as the data source. The name, efficacy classification and components of Polygonum multiflorum compatibility drugs were collected to establish a database. Polygonum multiflorum compatibility drug pairs were correlated,and the main compatibility components were analyzed. Results Totally 55 formulas were collected, of which253 were Traditional Chinese Medicine and 3 monomers. Most compatibility medicines were plant medicine,which were classified by function, including 56 tonity deficiency medicines(22.13%), 22 blood-activating and stasis-eliminating medicines(8.70%), 19 heat-clearing medicines(7.51%), 18 antirheumatic(7.11%), 17 Qi-regulating medicines(6.72%), 13 relieving exterior disorder medicines(5.14%), 13 calming liver wind medicines(5.14%) and 12 sedative medicines(4.74%). Altogether 36 compatibility pairs were obtained by correlation analysis. The compatible drugs were divided into 4 categories according to different components,and the main compatible components covered polysaccharides, saponins, flavonoids and glycosides. Conclusion Polygonum multiflorum is mainly used for tonity deficiency, invigorating blood circulation, and removing blood stasis in modern medicine. The types of compatible components are mainly polysaccharides, saponins,flavonoids and glycosides, followed by terpenoids, steroids, alkaloids and organic acids. This study might provide reference and ideas for research on the compatibility rules and mechanism of Polygonum multiflorum.
Objective To summarize the compatibility rules of Polygonum multiflorum in different formulations in Chinese pharmacopoeia(2015 Edition). Methods Preparations containing Polygonum multiflorum were used as the data source. The name, efficacy classification and components of Polygonum multiflorum compatibility drugs were collected to establish a database. Polygonum multiflorum compatibility drug pairs were correlated,and the main compatibility components were analyzed. Results Totally 55 formulas were collected, of which253 were Traditional Chinese Medicine and 3 monomers. Most compatibility medicines were plant medicine,which were classified by function, including 56 tonity deficiency medicines(22.13%), 22 blood-activating and stasis-eliminating medicines(8.70%), 19 heat-clearing medicines(7.51%), 18 antirheumatic(7.11%), 17 Qi-regulating medicines(6.72%), 13 relieving exterior disorder medicines(5.14%), 13 calming liver wind medicines(5.14%) and 12 sedative medicines(4.74%). Altogether 36 compatibility pairs were obtained by correlation analysis. The compatible drugs were divided into 4 categories according to different components,and the main compatible components covered polysaccharides, saponins, flavonoids and glycosides. Conclusion Polygonum multiflorum is mainly used for tonity deficiency, invigorating blood circulation, and removing blood stasis in modern medicine. The types of compatible components are mainly polysaccharides, saponins,flavonoids and glycosides, followed by terpenoids, steroids, alkaloids and organic acids. This study might provide reference and ideas for research on the compatibility rules and mechanism of Polygonum multiflorum.
引文
[1]中国药典2015年版.一部[S]. 2015:175-177.
[2]翟旭峰,李柯,娄勇军,等.中药何首乌炮制前后特征化学成分的分析[J].中南药学,2016,14(7):704-708.
[3]张伯礼,王永炎.方剂关键科学问题的基础研究——以组分配伍研制现代中药[J].中国天然药物,2005,3(5):258-261.
[4]张伯礼,王永炎,商洪才.组分配伍研制现代中药的理论和方法[J].继续医学教育,2006,20(19):89-91.
[5]陈桂芬,周常恩,李德森.基于关联规则挖掘技术对《千金方》中养生方剂配伍规律研究[J].长江大学学报(自然版),2014,11(36):208-212.
[6]蒋志滨,樊巧玲.基于关联分析和配伍网络的胃癌方剂用药规律分析[J].世界科学技术——中医药现代化,2015,17(4):871-874.
[7]匡海学.中药化学[M].北京:中国医药出版社,2013.
[8]高学敏.中药学[M].北京:中国中医药出版社,2007.
[9]卢多逊,李昉.开宝本草[M].辑复本.尚志钧辑校.合肥:安徽科学技术出版社,1998:253.
[10]韩诗雨.从《素问·上古天真论》之“男八女七”探讨肾脏与衰老的关系[J].中医药临床杂志,2017,29(1):76-78.
[11]王宗源.乌发抗衰方剂的研究[J].江苏中医,1993,(8):34-35.
[12]杨丽娟.从古方配伍探何首乌在乌发、生发中的应用[J].河南中医,2008,28(9):87-88.
[13]刘杨从,张建波,杜家波,等.气血双补丸致1例肝损伤不良反应[J].中南药学,2015,13(2):224.
[14]林艳,肖榕,李春,等.生/制/发酵何首乌化学成分、药理作用及肝毒性研究进展[J].中药新药与临床药理,2018,29(5):661-672.
[15]倪朱谟.本草汇言[M].郑金生点校.北京:中医古籍出版社,2006:260.
[16]陆以湉.冷庐医话[M].吕志连点校.北京:中医古籍出版社,1999:150.
[17]周欣,罗文佳,王丽平,等.基于“有故无陨”探讨何首乌不同成分毒性机制研究[J].辽宁中医药大学学报,2019,21(1):51-54.
[18]高峰,焦晨莉,余金花,等.基于“有故无陨”理论探讨何首乌对肾阴虚大鼠肝线粒体能量代谢的影响[J].中华中医药杂志,2018,33(11):5159-5162.
[19]林艳,肖榕,尹林子,等.基于粗糙集理论构建“谱毒”关系研究何首乌特异质肝毒性物质基础[J].中国中药杂志,2018,44(3):509-517.
[20]梁晓东,张茜,边月娟,等. HPLC测定还脑益聪方及配伍前后何首乌肝毒性成分含量变化[J].中华中医药学刊,2018,36(7):1557-1561.
[21]林飞,胡锡琴,谢人明.何首乌配伍茯苓解毒机理的研究[J].中药药理与临床,2009,26(5):79-80.
[2]翟旭峰,李柯,娄勇军,等.中药何首乌炮制前后特征化学成分的分析[J].中南药学,2016,14(7):704-708.
[3]张伯礼,王永炎.方剂关键科学问题的基础研究——以组分配伍研制现代中药[J].中国天然药物,2005,3(5):258-261.
[4]张伯礼,王永炎,商洪才.组分配伍研制现代中药的理论和方法[J].继续医学教育,2006,20(19):89-91.
[5]陈桂芬,周常恩,李德森.基于关联规则挖掘技术对《千金方》中养生方剂配伍规律研究[J].长江大学学报(自然版),2014,11(36):208-212.
[6]蒋志滨,樊巧玲.基于关联分析和配伍网络的胃癌方剂用药规律分析[J].世界科学技术——中医药现代化,2015,17(4):871-874.
[7]匡海学.中药化学[M].北京:中国医药出版社,2013.
[8]高学敏.中药学[M].北京:中国中医药出版社,2007.
[9]卢多逊,李昉.开宝本草[M].辑复本.尚志钧辑校.合肥:安徽科学技术出版社,1998:253.
[10]韩诗雨.从《素问·上古天真论》之“男八女七”探讨肾脏与衰老的关系[J].中医药临床杂志,2017,29(1):76-78.
[11]王宗源.乌发抗衰方剂的研究[J].江苏中医,1993,(8):34-35.
[12]杨丽娟.从古方配伍探何首乌在乌发、生发中的应用[J].河南中医,2008,28(9):87-88.
[13]刘杨从,张建波,杜家波,等.气血双补丸致1例肝损伤不良反应[J].中南药学,2015,13(2):224.
[14]林艳,肖榕,李春,等.生/制/发酵何首乌化学成分、药理作用及肝毒性研究进展[J].中药新药与临床药理,2018,29(5):661-672.
[15]倪朱谟.本草汇言[M].郑金生点校.北京:中医古籍出版社,2006:260.
[16]陆以湉.冷庐医话[M].吕志连点校.北京:中医古籍出版社,1999:150.
[17]周欣,罗文佳,王丽平,等.基于“有故无陨”探讨何首乌不同成分毒性机制研究[J].辽宁中医药大学学报,2019,21(1):51-54.
[18]高峰,焦晨莉,余金花,等.基于“有故无陨”理论探讨何首乌对肾阴虚大鼠肝线粒体能量代谢的影响[J].中华中医药杂志,2018,33(11):5159-5162.
[19]林艳,肖榕,尹林子,等.基于粗糙集理论构建“谱毒”关系研究何首乌特异质肝毒性物质基础[J].中国中药杂志,2018,44(3):509-517.
[20]梁晓东,张茜,边月娟,等. HPLC测定还脑益聪方及配伍前后何首乌肝毒性成分含量变化[J].中华中医药学刊,2018,36(7):1557-1561.
[21]林飞,胡锡琴,谢人明.何首乌配伍茯苓解毒机理的研究[J].中药药理与临床,2009,26(5):79-80.